

## SARC Semiannual Meeting Agenda

Friday, June 3, 2022 · 8:00 am – 12:00 pm CT

Hyatt Centric Chicago Magnificent Mile (Grand Ballroom)

7:30	<b>Breakfast &amp; Opening Session</b>	
8:00	<b>Welcome</b>	<b>Jonathan Fletcher MD (CSO)</b> <b>Steven Young (CEO)</b>
8:05	<b>Ars longa, vita brevis: accelerating translation and collaboration to develop effective new therapies for sarcoma patients</b>  • Q&A	<b>George Demetri MD</b> Division Chief – Sarcoma Center Senior VP for Experimental Therapeutics Co-Director, Ludwig Center Dana-Farber/Harvard Cancer Center
8:45	<b>SARC Symposium</b>	
	<b>Introduction</b>	<b>Co-Moderators:</b> <b>Sandra D’Angelo MD</b> (Memorial Sloan Kettering Cancer Institute) <b>Seth Pollack MD</b> (Northwestern U.)
8:45	<b>“Emerging Checkpoints in Sarcoma”</b>	<b>Bree Wilky MD</b> (University of Colorado Cancer Center)
9:05	<b>“Targeting fusions in sarcoma with T cell therapy”</b>	<b>Lauren Banks MD PhD</b> (Memorial Sloan Kettering Cancer Institute)
9:25	<b>“CAR T Cell Therapy in Sarcoma”</b>	<b>Navin Pinto MD</b> (University of Washington, Seattle Children’s Hospital)
9:45	• <b>Discussion/Q&amp;A</b>	<b>Speakers &amp; Co-Moderators</b>
10:15	<b>Break (15 minutes)</b>	
10:30	<b>SARC Career Development Award</b>	
	<b>CDA Award History &amp; Impact</b> <b>2022 Award Announcement</b>	<b>CDA Selection Committee</b> <b>Recipient</b>
10:50	<b>SARC Trials: Currently Enrolling</b>	<b>Presenter (bolded)</b>
	<b>Introduction</b>	<b>Scott Okuno MD</b> (SARC Medical Officer)
	<b>SARC031:</b> Phase 2 MEK inhibitor selumetinib w/ dual mTOR kinase inhibitor sirolimus in MPNST	<b>AeRang Kim MD, PhD (PI)</b> <b>Brigitte Widemann MD (co-PI)</b>
	<b>SARC032:</b> Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity	<b>David Kirsch MD, PhD (PI)</b> <b>Yvonne Mowery MD PhD (co-I)</b>
	<b>SARC033:</b> Phase 2 Trametinib in Unresectable or Metastatic Epithelioid Hemangioendothelioma	<b>Scott Schuetze MD</b> <b>Libby Davis MD (co-I)</b>
	<b>SARC037:</b> Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging	<b>Patrick Grohar MD, PhD (PI)</b>
	<b>SARC038:</b> Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma	<b>Fariba Navid MD (PI)</b> <b>Lara Davis, MD (co-PI)</b>
	<b>SARC041:</b> Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	<b>Mark Dickson MD (PI)</b>
	• <b>Q&amp;A/Panel Discussion</b>	<b>Speakers &amp; Medical Officer</b>
11:35	<b>SARC Mission &amp; Evolution</b>	
	<b>Present &amp; Future</b>	<b>Chappie Conrad MD</b> (Board Chair) <b>Jonathan Fletcher MD (CSO)</b> <b>Steven Young</b> (President & CEO)
12:00	<b>Adjourn</b>	